You have been told you have IBS-D. You have tried dietary changes, loperamide, possibly antispasmodics or a low-dose antidepressant. The diarrhea persists. At some point, the question shifts from how to manage IBS symptoms to whether IBS is the right diagnosis. Microscopic colitis is one of the most common treatable conditions that hides behind an IBS-D label, and it has a specific diagnostic pathway that many patients have never been offered. The colon looks normal on colonoscopy, which is exactly why the condition gets missed. Diagnosis requires biopsies of normal-appearing tissue, a step that is not always performed. This guide covers the practical steps for getting tested: what to request, how the biopsies work, what a medication review should include, and how a budesonide trial can provide both treatment and diagnostic clarity.
When should you push for microscopic colitis testing?
Several clinical scenarios warrant specific testing for microscopic colitis rather than continuing to manage symptoms under an IBS-D framework. Consider pursuing testing if you have chronic watery diarrhea (3 or more watery stools daily) that has not improved with standard IBS treatments over 3 or more months. Testing is also warranted if your colonoscopy was reported as normal but did not include random biopsies, if you are a woman over 50 with relatively recent onset of chronic diarrhea, if you take PPIs, NSAIDs, or SSRIs and your diarrhea began or worsened after starting them, if you have nocturnal diarrhea (waking from sleep to have bowel movements), or if your diarrhea is high-volume and watery without significant abdominal pain as the primary symptom.
None of these features alone confirms microscopic colitis. But when multiple features are present and IBS treatments are failing, the probability is high enough that specific testing is both clinically justified and cost-effective compared to continuing empiric IBS management.
The biopsy protocol: what to request
The diagnostic test for microscopic colitis is colonoscopy with random biopsies. The word 'random' is important here. Unlike biopsies taken from visually abnormal tissue (polyps, ulcers, discolored patches), these biopsies are taken from mucosa that looks completely healthy. This is counterintuitive for many endoscopists trained to biopsy only what looks abnormal, which is one reason the practice is inconsistent.
Biopsy sites
European guidelines recommend biopsies from at least two locations in the right colon (cecum and ascending colon) and at least two locations in the left colon (descending colon and sigmoid). A minimum of 2 biopsies from each site is standard, giving a total of at least 8 tissue samples. Some protocols recommend additional biopsies from the transverse colon. The multi-site approach is necessary because microscopic colitis changes can be patchy. Biopsies from a single segment can yield a false negative if that particular area is not affected. Right-sided biopsies are particularly important because collagenous colitis is often more prominent in the proximal colon.
What the pathologist looks for
The pathologist examines the biopsy samples for two key findings. For collagenous colitis: a thickened subepithelial collagen band exceeding 10 micrometers (normal is 3-5 micrometers), along with increased inflammatory cells in the lamina propria. For lymphocytic colitis: greater than 20 intraepithelial lymphocytes per 100 surface epithelial cells, without significant collagen thickening. Surface epithelial damage and increased lamina propria cellularity may also be present in both subtypes. The pathology report should specifically comment on collagen band thickness and intraepithelial lymphocyte counts. If the report simply states 'no significant pathology' without mentioning these specific measurements, ask your gastroenterologist to confirm that microscopic colitis was specifically evaluated.
âšī¸Before your colonoscopy, tell your gastroenterologist explicitly that you want random biopsies from the right and left colon to evaluate for microscopic colitis, even if everything looks normal. This request should be documented in your procedure consent and instructions so it is not overlooked during the examination.
Medication review: the step that gets skipped
A thorough medication review should happen before or alongside the biopsy workup. Drug-induced microscopic colitis is common enough that identifying and removing the trigger can resolve the condition entirely, sometimes without needing budesonide. The review should cover all current medications and any that were started in the months before diarrhea symptoms began.
| Drug Class | Examples | Evidence Level | Action |
|---|---|---|---|
| Proton pump inhibitors | Omeprazole, lansoprazole, esomeprazole, pantoprazole | Strong association | Discuss switching to H2 blocker or discontinuing if possible |
| NSAIDs | Ibuprofen, naproxen, aspirin (high-dose) | Strong association | Discuss alternative pain management |
| SSRIs | Sertraline, fluoxetine, paroxetine | Moderate association | Discuss alternative antidepressant class |
| Statins | Atorvastatin, simvastatin, rosuvastatin | Weaker association | Consider if no other trigger identified |
| Checkpoint inhibitors | Nivolumab, pembrolizumab, ipilimumab | Strong association | Coordinate with oncology team |
The temporal relationship is the strongest clue. If chronic diarrhea began within weeks to 3 months of starting a medication on this list, drug-induced microscopic colitis is a strong possibility. A trial of medication discontinuation (with appropriate substitution and physician guidance) can be both diagnostic and therapeutic. If diarrhea resolves within 2-4 weeks of stopping the suspected medication, drug-induced microscopic colitis is the likely diagnosis.
The budesonide trial: treatment as diagnosis
Budesonide occupies a unique position in the microscopic colitis diagnostic pathway because it serves as both first-line treatment and diagnostic confirmation. The standard protocol is budesonide 9 mg daily (typically 3 mg three times daily or 9 mg once daily) for 6-8 weeks. In more than 80% of patients with microscopic colitis, this produces clinical remission, defined as fewer than 3 stools per day without watery consistency.
The timeline of response provides diagnostic information. Most responders notice meaningful improvement within 2-4 weeks, often sooner. A reduction from 6-8 watery stools daily to 1-2 formed stools within the first two weeks is a characteristic microscopic colitis response. IBS-D does not produce this response pattern with budesonide because there is no mucosal inflammation for the drug to target. If budesonide produces no improvement after a full 8-week trial, microscopic colitis is unlikely, and the IBS-D diagnosis becomes more credible.
What happens after the initial trial?
If budesonide produces remission, the next step is a taper. The standard approach reduces the dose from 9 mg to 6 mg daily for 2-4 weeks, then 3 mg daily for 2-4 weeks, then discontinuation. Relapse is common. Studies show that 60-80% of patients relapse within 6 months of stopping budesonide. For these patients, low-dose maintenance therapy at 3-6 mg daily is often necessary long-term. The relapse pattern itself provides additional diagnostic confirmation. If symptoms return predictably when budesonide is tapered and resolve when it is restarted, the diagnosis of microscopic colitis is essentially confirmed by treatment response, even if the initial biopsies were equivocal.
What about non-invasive markers?
Fecal calprotectin, a stool marker of intestinal inflammation, is sometimes elevated in microscopic colitis but is not reliable enough to diagnose or exclude the condition. Studies show that calprotectin levels in microscopic colitis are generally lower than in Crohn's disease or ulcerative colitis and overlap significantly with normal values. A normal fecal calprotectin does not rule out microscopic colitis. An elevated level in a patient with chronic diarrhea supports the possibility of an inflammatory cause but cannot distinguish between microscopic colitis and other inflammatory conditions. C-reactive protein and ESR are similarly unreliable for microscopic colitis detection. At present, there is no non-invasive test that can replace colonic biopsies for diagnosis. Research into newer biomarkers is ongoing, but none have reached clinical validation.
What helps with tracking symptoms during the diagnostic process?
Documenting your symptoms before and during the testing and treatment process gives your gastroenterologist the objective data needed to interpret results and assess treatment response. Record the number of bowel movements per day, stool consistency (use the Bristol Stool Scale), the presence or absence of nocturnal episodes, and any relationship to specific foods or medications. The GLP1Gut app can streamline this by tracking stool frequency, consistency, and symptom patterns over time, producing a shareable timeline that helps your doctor evaluate whether a budesonide trial is producing a genuine response or whether symptoms are fluctuating independently. Start logging at least 2 weeks before your colonoscopy or budesonide trial to establish a baseline.
A step-by-step testing plan
Practical steps when IBS-D treatment is failing
- Step 1: Review your colonoscopy report. Check whether random biopsies were taken. If not, microscopic colitis has not been evaluated.
- Step 2: Review your medication list with your doctor. Flag PPIs, NSAIDs, SSRIs, statins, and any medication started before your diarrhea began.
- Step 3: If biopsies were not taken previously, schedule a colonoscopy with explicit instructions for random biopsies from the right and left colon (minimum 2 sites each side, at least 2 biopsies per site).
- Step 4: If biopsies are positive for collagenous or lymphocytic colitis, begin budesonide 9 mg daily for 6-8 weeks.
- Step 5: If biopsies are negative but clinical suspicion remains high, discuss a budesonide therapeutic trial with your gastroenterologist.
- Step 6: If a drug trigger is suspected, discuss a supervised medication discontinuation trial with appropriate substitution.
- Step 7: Track symptoms throughout the process to document response or lack of response to each intervention.
Frequently Asked Questions
Can I ask for a repeat colonoscopy just to get biopsies?
Yes. If your previous colonoscopy did not include random biopsies and you have persistent chronic diarrhea not responding to IBS treatments, requesting a repeat colonoscopy specifically for microscopic colitis evaluation is clinically reasonable. Explain to your gastroenterologist that you want biopsies from normal-appearing mucosa in both the right and left colon. Insurance coverage for repeat colonoscopy varies, so check with your plan.
How long does it take to get biopsy results?
Pathology results from colonic biopsies typically take 5-10 business days. The pathologist examines the tissue for collagen band thickness and intraepithelial lymphocyte counts. Ask your gastroenterologist to ensure the pathology request specifically mentions evaluation for microscopic colitis, so the pathologist knows to look for these features.
Are there side effects of budesonide I should know about?
Budesonide has lower systemic absorption than other corticosteroids like prednisone, but side effects can still occur. Common effects include headache, nausea, and upper respiratory symptoms. Long-term use at higher doses can cause adrenal suppression, bone density loss, and elevated blood sugar. Low-dose maintenance (3 mg daily) has a more favorable side effect profile. Discuss monitoring needs with your doctor, especially if you require long-term therapy.
What if my biopsies are negative but I respond to budesonide?
This scenario can occur if biopsies were taken from unaffected segments (due to patchy distribution) or if the histological changes were subtle and not captured in the samples. A clear clinical response to budesonide in the setting of chronic watery diarrhea is clinically meaningful even if biopsies are negative. Your gastroenterologist may consider this a probable microscopic colitis diagnosis and manage accordingly.
Will I need to take budesonide long-term?
Many patients require long-term low-dose budesonide maintenance. After an initial remission at 9 mg daily, the dose is tapered. If symptoms return during the taper (which happens in 60-80% of patients), long-term maintenance at the lowest effective dose (typically 3-6 mg daily) is standard practice. Some patients eventually achieve stable remission and can discontinue. Your doctor will help determine the right approach based on your relapse pattern.
â ī¸This article is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition.